Patents by Inventor Shannon R. Fix-Stenzel

Shannon R. Fix-Stenzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
    Patent number: 8691810
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R1, R2, R3, R4a, R5, and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: April 8, 2014
    Assignee: AbbVie Inc.
    Inventors: Michael R. Michaelides, Andrew S. Judd, Shannon R. Fix-Stenzel, Richard F. Clark, Bryan K. Sorensen, Zhiqin Ji
  • Sphingosine-1-phosphate receptor agonist and antagonist compounds
    Patent number: 8217027
    Abstract: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: July 10, 2012
    Assignee: Abbott Laboratories
    Inventors: Grier A. Wallace, Eric C. Breinlinger, Kevin P. Cusack, Shannon R. Fix-Stenzel, Thomas D. Gordon, Adrian D. Hobson, Martin E. Hayes, Graham K. Ansell, Pintipa Grongsaard
  • PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES
    Publication number: 20110281842
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R1, R2, R3, R4a, R5, and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.
    Type: Application
    Filed: May 12, 2011
    Publication date: November 17, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael R. Michaelides, Andrew S. Judd, Shannon R. Fix-Stenzel, Richard F. Clark, Bryan K. Sorensen, Zhiqin Ji
  • Novel Oxadiazole Compounds
    Publication number: 20110207704
    Abstract: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.
    Type: Application
    Filed: August 24, 2010
    Publication date: August 25, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Kevin P. Cusack, Eric C. Breinlinger, Shannon R. Fix-Stenzel, Robert H. Stoffel, Kevin R. Woller, Adrian D. Hobson, Pintipa Grongsaard
  • Oxadiazole compounds
    Patent number: 7834039
    Abstract: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: November 16, 2010
    Assignee: Abbott Laboratories
    Inventors: Adrian D. Hobson, Shannon R. Fix-Stenzel, Kevin P. Cusack, Eric C. Breinlinger, Graham K. Ansell, Robert H. Stoffel, Kevin R. Woller, Pintipa Grongsaard
  • Sphingosine-1-phosphate receptor agonist and antagonist compounds
    Publication number: 20090029947
    Abstract: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
    Type: Application
    Filed: March 11, 2008
    Publication date: January 29, 2009
    Inventors: Grier A. Wallace, Eric C. Breinlinger, Kevin P. Cusack, Shannon R. Fix-Stenzel, Thomas D. Gordon, Adrian D. Hobson, Martin E. Hayes, Graham K. Ansell, Pintipa Grongsaard
  • Novel oxadiazole compounds
    Publication number: 20080280876
    Abstract: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.
    Type: Application
    Filed: December 14, 2007
    Publication date: November 13, 2008
    Inventors: Adrian D. Hobson, Shannon R. Fix-Stenzel, Kevin P. Cusack, Eric C. Breinlinger, Graham K. Ansell, Robert H. Stoffel